Trials that use: Log-rank test
New to this method? Read the tutorial →
368 results
- Effect of Clonazepam on Cannabis Withdrawal and Relapse in Treatment-seeking Patients: Complete Statistical AnalysisIndependent statistical analysis of Effect of Clonazepam on Cannabis Withdrawal and Relapse in Treatment-seeking Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19: Complete Statistical AnalysisIndependent statistical analysis of Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Effects of Perioperative Nesiritide or Milrinone Infusion on Recovery From Fontan Surgery: Complete Statistical AnalysisIndependent statistical analysis of Effects of Perioperative Nesiritide or Milrinone Infusion on Recovery From Fontan Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors: Complete Statistical AnalysisIndependent statistical analysis of Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes: Complete Statistical AnalysisIndependent statistical analysis of Efficacy and Safety of Famciclovir 1-day Treatment Compared to 3-day Treatment With Valacyclovir in Adults With Recurrent Genital Herpes: primary endpoint results, effect estimate with confidence interval, sample-size…
- Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02): Complete Statistical AnalysisIndependent statistical analysis of Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02): primary endpoint results, effect estimate…
- Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma: Complete Statistical AnalysisIndependent statistical analysis of Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Efficacy and Safety of the Lidoderm Patch Applied to Patients With Osteoarthritis of the Knee: Complete Statistical AnalysisIndependent statistical analysis of Efficacy and Safety of the Lidoderm Patch Applied to Patients With Osteoarthritis of the Knee: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Electric Muscle Stimulation for Patients With Chronic Respiratory Failure: Complete Statistical AnalysisIndependent statistical analysis of Electric Muscle Stimulation for Patients With Chronic Respiratory Failure: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01930643).
- ELEVATEIndependent statistical analysis of DC Migration Study for Newly-Diagnosed GBM: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02366728).
- Eltrombopag Phase III Study In Chinese Chronic ITP Patients: Complete Statistical AnalysisIndependent statistical analysis of Eltrombopag Phase III Study In Chinese Chronic ITP Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01762761).
- EMBRACAIndependent statistical analysis of the EMBRACA phase 3 trial of talazoparib versus physician's choice treatment in advanced and/or metastatic breast cancer patients with BRCA mutation, including progression-free survival, response, overall survival, quality…
- EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX: Complete Statistical AnalysisIndependent statistical analysis of EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- ENGAGE AF-TIMI 48Independent statistical analysis of ENGAGE AF-TIMI 48, evaluating edoxaban versus warfarin for stroke and systemic embolic events in patients with atrial fibrillation.
- EPIC-SRIndependent statistical analysis of EPIC-SR (NCT05011513), the randomized, placebo-controlled phase 2/3 trial of nirmatrelvir plus ritonavir in standard-risk COVID-19, covering the log-rank primary analysis, logistic-regression odds ratios, negative binomial modelling and serious…
- EQUATORIndependent statistical analysis of Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma: Complete Statistical AnalysisIndependent statistical analysis of Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations: Complete Statistical AnalysisIndependent statistical analysis of Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- EURAMOS-1Complete statistical analysis of EURAMOS-1, a randomized phase 3 trial of combination chemotherapy, peginterferon alfa-2b, and surgery in patients with localized or metastatic osteosarcoma.
- EURTACIndependent statistical analysis of EURTAC, a randomized phase 3 trial comparing erlotinib with standard chemotherapy in advanced non-small cell lung cancer with EGFR TK-domain mutations, including progression-free survival, overall survival, trial design,…
- EVADEComplete statistical analysis of the randomized phase 2/3 EVADE trial of ADG20 for the prevention of COVID-19, including trial design, primary and secondary endpoints, risk differences, hazard ratios, statistical methodology, safety, and…
- Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With Schizophrenia: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With Schizophrenia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05011513).
- Evaluation of SQ109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design: Complete Statistical AnalysisIndependent statistical analysis of Evaluation of SQ109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- EXAMINERIndependent statistical analysis of A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- ExCelA complete statistical analysis of the ExCel phase 3 trial of exemestane for breast cancer prevention in postmenopausal women at increased risk, including trial design, breast cancer-free survival, hazard ratios, confidence intervals,…
- Exemestane in Treating Postmenopausal Women With Stage IV Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Exemestane in Treating Postmenopausal Women With Stage IV Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00810797).
- EXPEDITEComplete statistical analysis of the EXPEDITE phase 3 trial comparing misoprostol vaginal insert with dinoprostone vaginal insert for reducing time to vaginal delivery during induction of labor.
- ExteNETIndependent statistical analysis of the phase 3 ExteNET trial of neratinib after adjuvant trastuzumab in women with early stage breast cancer, including randomized design, time-to-event endpoints, hazard ratios, confidence intervals, survival methodology,…
- FACEIndependent statistical analysis of the FACE phase 3 trial comparing letrozole with anastrozole in the adjuvant treatment of postmenopausal women with hormone receptor and node positive breast cancer.
- Fast-track Rehabilitation After Elective Colorectal and Small Bowel Resection: Complete Statistical AnalysisIndependent statistical analysis of Fast-track Rehabilitation After Elective Colorectal and Small Bowel Resection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00606944).
- FEM-PrEPIndependent statistical analysis of FEM-PrEP, a randomized phase 3 trial evaluating Truvada versus placebo for preventing HIV acquisition in women, including its time-to-event analysis, safety endpoints, secondary outcomes, and statistical interpretation.
- FIDELIO-DKDIndependent statistical analysis of Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- FIGARO-DKDIndependent statistical analysis of FIGARO-DKD, a randomized phase 3 trial of finerenone versus placebo in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease.
- FIGHT-302Independent statistical analysis of FIGHT-302, a randomized phase 3 trial of pemigatinib versus gemcitabine plus cisplatin in unresectable or metastatic cholangiocarcinoma, including progression-free survival, response, overall survival, statistical methodology, safety, and interpretation.
- First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01524991).
- First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC: Complete Statistical AnalysisIndependent statistical analysis of First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- FLAURA2Independent statistical analysis of FLAURA2, the randomized phase 3 trial of osimertinib with chemotherapy versus osimertinib alone in first-line treatment of EGFR-mutated non-small cell lung cancer. Includes trial design, endpoints, survival analyses,…
- FOCUSIndependent statistical analysis of A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01688336).
- FREEDOMIndependent statistical analysis of the FREEDOM trial comparing coronary artery bypass grafting with percutaneous coronary intervention in individuals with diabetes and multivessel coronary artery disease, including time-to-event methods, reported results, safety, and…
- GAVOTTEIndependent statistical analysis of A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS): primary endpoint results, effect…
- Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval,…
- Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- GLOWIndependent statistical analysis of the phase 3 GLOW trial of zolbetuximab plus CAPOX versus placebo plus CAPOX in CLDN 18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinoma, including time-to-event methodology, reported efficacy results,…